The estimated Net Worth of Olivia Kyusuk Bloom is at least $3.09 Milion dollars as of 8 February 2023. Ms. Bloom owns over 400,000 units of Geron stock worth over $2,083,441 and over the last 13 years she sold GERN stock worth over $91,632. In addition, she makes $912,467 as Chief Financial Officer, Executive Vice President - Finance oraz Treasurer at Geron.
Sign up
Ms. Bloom GERN stock SEC Form 4 insiders trading
Olivia has made over 8 trades of the Geron stock since 2011, according to the Form 4 filled with the SEC. Most recently she exercised 400,000 units of GERN stock worth $604,000 on 8 February 2023.
The largest trade she's ever made was exercising 400,000 units of Geron stock on 8 February 2023 worth over $604,000. On average, Olivia trades about 15,529 units every 153 days since 2011. As of 8 February 2023 she still owns at least 474,588 units of Geron stock.
You can see the complete history of Ms. Bloom stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Olivia Bloom biography
Olivia K. Bloom serves as Chief Financial Officer, Executive Vice President - Finance, Treasurer of the Company. Ms. Bloom has served as our Executive Vice President, Finance since February 2014, Chief Financial Officer since December 2012 and Treasurer since February 2011. Ms. Bloom previously served as our Senior Vice President, Finance from December 2012 to February 2014, Chief Accounting Officer from September 2010 to December 2012 and Vice President, Finance from January 2007 to December 2012. Ms. Bloom joined the Company in 1994 as a Senior Financial Analyst and from 1996 to 2011 served as our Controller. Prior to joining Geron, Ms. Bloom started her career in public accounting at KPMG Peat Marwick and became a Certified Public Accountant in 1994. Ms. Bloom graduated Phi Beta Kappa with a B.S. in Business Administration from the University of California at Berkeley.
What is the salary of Olivia Bloom?
As the Chief Financial Officer, Executive Vice President - Finance oraz Treasurer of Geron, the total compensation of Olivia Bloom at Geron is $912,467. There are 5 executives at Geron getting paid more, with John Scarlett having the highest compensation of $1,941,140.
How old is Olivia Bloom?
Olivia Bloom is 51, she's been the Chief Financial Officer, Executive Vice President - Finance oraz Treasurer of Geron since 2014. There are 15 older and 4 younger executives at Geron. The oldest executive at Geron Corp. is Stephen N. Rosenfield, 71, who is the Exec. VP, Chief Legal Officer & Corp. Sec..
What's Olivia Bloom's mailing address?
Olivia's mailing address filed with the SEC is C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Insiders trading at Geron
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury oraz Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
What does Geron do?
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
What does Geron's logo look like?
Complete history of Ms. Bloom stock trades at Geron i Personalis Inc
Geron executives and stock owners
Geron executives and other stock owners filed with the SEC include:
-
John Scarlett,
Chairman of the Board, President, Chief Executive Officer -
Aleksandra Rizo,
Executive Vice President, Chief Medical Officer -
Dr. John A. Scarlett,
CEO, Pres & Chairman -
Stephen Rosenfield,
Executive Vice President, Corporate Secretary, Chief Legal Officer -
Andrew Grethlein,
Executive Vice President, Chief Operating Officer -
Olivia Bloom,
Chief Financial Officer, Executive Vice President - Finance, Treasurer -
Melissa Kelly Behrs,
Executive Vice President, Chief Business Officer -
Dr. Aleksandra Rizo M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Dr. Andrew J. Grethlein,
Exec. VP & COO -
Melissa A. Kelly Behrs,
Exec. VP of Bus. Operations & Chief Alliance Officer -
Olivia Kyusuk Bloom,
Exec. VP of Fin., CFO & Treasurer -
Elizabeth O'Farrell,
Independent Director -
Dawn Bir,
Independent Director -
Karin Eastham,
Lead Independent Director -
V. Bryan Lawlis,
Independent Director -
Robert Spiegel,
Independent Director -
Susan Molineaux,
Independent Director -
Anil Kapur,
Executive Vice President, Corporate Strategy and Chief Commercial Officer -
Edward E. Koval,
Exec. VP & Chief Bus. Officer -
Anil Kapur,
Chief Commercial Officer & Exec. VP of Corp. Strategy -
Stephen N. Rosenfield,
Exec. VP, Chief Legal Officer & Corp. Sec. -
Shannon Odam,
VP of HR -
Suzanne Messere,
Head of Investor Relations & Corp. Communications -
Daniel Bradbury,
Director -
Thomas Hofstaetter,
Director -
Hoyoung Huh,
Director -
James Ziegler,
EVP, Chief Commercial Officer -
Gaurav Aggarwal,
-
Calvin Harley,
Chief Scientific Officer -
Graham K Cooper,
EVP, Bus Dev & CFO -
Katharine E. Spink,
VP Operations, Regen Med Progs -
Jane Lebkowski,
VP Regenerative Medicine -
David Greenwood,
SVP Corporate Development and -
Melanie I Nallicheri,
SVP Corp Dev -
Alexander E Barkas,
Director -
Charles J Homcy,
Director -
Thomas Okarma,
President and CEO -
Patrick J Zenner,
Director -
Fabio M Benedetti,
SVP, Chief Med Off, Oncology -
John Peter Walker,
Director -
Alan Colowick,
President, Oncology -
Robert B Stein,
Director -
Stephen Michael Kelsey,
EVP, CMO, Oncology -
Edward V Fritzky,
Director -
Craig C Parker,
SVP, Corporate Development -
David Earp,
VP Intellectual Property -
Thomas Kiley,
Director -
Bioscience Inc Merix,
10% owner -
William Stempel,
VP and General Counsel -
John F Mc Donald,
-
Faye Feller,
EVP, Chief Medical Officer -
Scott Alan Samuels,
EVP, Chief Legal Officer -
Michelle Robertson,
EVP, Chief Financial Officer